Skip to main content
S&P 5007,585.73-0.45%DOW52,093.11-0.63%NASDAQ25,981.57-0.78%BTC$75,900.00-1.51%ETH$2,404.54-3.20%GOLD$4,387.30+1.26%OIL$103.71-2.00%
Smart Investors Daily
Avalo Therapeutics, Inc. logo

NASDAQ · AVTX

Avalo Therapeutics, Inc.

Healthcare · Biotechnology

$16.07

Down-$0.11 (-0.68%)

Updated Sep 16, 2026, 11:07 AM

SID Score

3.6/10

Composite research score

Smart Money

—

Institutional and insider signal

Market cap
220.35M
P/E ratio
-2.73
Dividend yield
0.00%
52-week range
$12.51 – $24.27
Volume
1.1M
Avg. volume
410.27K

Price performance

AVTX price history

1M range · 0 trading sessions · Daily adjusted prices

AVTX does not have enough price history for the selected period.

Data unavailable

Market data is busy. Please try again shortly.

Latest AVTX news

The latest Smart Investors Daily articles mentioning AVTX.

Stock researchCompany · Overview

AVTX research

Overview

Company profile and research snapshot.

Company profile

Avalo Therapeutics Inc is a clinical-stage biotechnology company focused on the treatment of immune dysregulation. The company's asset is AVTX-009, an anti-IL-1B monoclonal antibody ("mAb"), targeting inflammatory diseases. Avalo's pipeline also includes quisovalimab (anti-LIGHT mAb) and AVTX-008 (BTLA agonist fusion protein).

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
—
Average target
$25.00
Implied upside
—
Analysts
—
AVTX recent ratings
DateFirmRatingTarget
Aug 7, 2026GuggenheimBuy—
Aug 7, 2026HC Wainwright & Co.Buy—
Jul 6, 2026Leerink PartnersOutperform—
Jun 16, 2026BTIGBuy—
Jun 12, 2026B of A SecuritiesBuy—
Open full forecast

News briefing

No generated briefing is available yet.

Yahoo · Sep 4, 2026

Avalo Therapeutics Announces Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4)

WAYNE, Pa., Sept. 04, 2026 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (Nasdaq: AVTX), a clinical stage biotechnology company dedicated to developing therapeutics targeting the IL-1β pathway for immune-mediated inflammatory diseases, today announced the grant of inducement equity awards to six new employees. The Compensation Committee of the Board of Directors of Avalo approved the grants of nonstatutory stock options to purchase an aggregate of 78,000 shares of common stock (the “Options”) as

Yahoo · Sep 3, 2026

Avalo Therapeutics to Participate in Upcoming Investor Conferences

WAYNE, Pa., Sept. 03, 2026 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (Nasdaq: AVTX), a clinical stage biotechnology company dedicated to developing therapeutics targeting the IL-1β pathway for immune-mediated inflammatory diseases, today announced that management will participate in the following investor conferences: Cantor Global Healthcare Conference 2026 Fireside ChatSeptember 10, 2026, at 8:00 am ET Morgan Stanley 24th Annual Global Healthcare Conference 1x1 meetings onlySeptember 16, 20

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.

Featured By